2 Sleep Apnea Stocks in Focus Today
Portfolio Pulse from
Eli Lilly and Co (NYSE:LLY) received FDA approval for its weight-loss drug, Zepbound, to treat obstructive sleep apnea in adults with obesity, marking the first such treatment in the U.S.
December 23, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's weight-loss drug, Zepbound, has been approved by the FDA to treat obstructive sleep apnea in adults with obesity, marking a significant milestone as the first treatment of its kind in the U.S.
The FDA approval of Zepbound is a significant development for Eli Lilly, as it introduces a novel treatment for sleep apnea in obese adults, potentially opening a new market and revenue stream. This approval is likely to positively impact LLY's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100